Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bu Shen Na Qi is a Traditional Chinese Medicine (TCM) herbal formula primarily indicated for the treatment of chronic respiratory disorders, including bronchial asthma and chronic obstructive pulmonary disease (COPD). The formula is designed to address the TCM syndrome of 'Kidney deficiency and failure to receive Qi,' a state characterized by chronic wheezing and shortness of breath where the 'Kidney' is unable to assist the 'Lung' in inhalation. It typically consists of a combination of herbs such as Rehmannia glutinosa, Schisandra chinensis, and Psoralea corylifolia. In clinical research, such as studies conducted by the Shanghai University of Traditional Chinese Medicine, it is evaluated for its ability to improve lung function, reduce airway inflammation, and decrease the frequency of asthma exacerbations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bu shen na qi.